Cytokeratin 17 Polyklonaler Antikörper

Cytokeratin 17 Polyklonal Antikörper für WB, IHC, IF/ICC, IP, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus, Ratte und mehr (1)

Anwendung

WB, IHC, IF/ICC, IP, ELISA

Konjugation

Unkonjugiert

Publikationen(4)

Kat-Nr. : 18502-1-AP

Synonyme

KRT17, Keratin-17, keratin 17, Cytokeratin-17, Cytokeratin,Keratin



Geprüfte Anwendungen

Erfolgreiche Detektion in WBHeLa-Zellen, A431-Zellen
Erfolgreiche IPHeLa-Zellen
Erfolgreiche Detektion in IHChumanes Zervixkarzinomgewebe, humanes Kolonkarzinomgewebe, humanes Lungenkarzinomgewebe, humanes Pankreaskarzinomgewebe, humanes Hautgewebe
Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.
Erfolgreiche Detektion in IF/ICCHeLa-Zellen

Empfohlene Verdünnung

AnwendungVerdünnung
Western Blot (WB)WB : 1:500-1:3000
Immunpräzipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunhistochemie (IHC)IHC : 1:20-1:200
Immunfluoreszenz (IF)/ICCIF/ICC : 1:200-1:800
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Produktinformation

18502-1-AP bindet in WB, IHC, IF/ICC, IP, ELISA Cytokeratin 17 und zeigt Reaktivität mit human, Maus, Ratten

Getestete Reaktivität human, Maus, Ratte
In Publikationen genannte Reaktivitäthuman, Maus, Ziege
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen Cytokeratin 17 fusion protein Ag13351
Vollständiger Name keratin 17
Berechnetes Molekulargewicht 48 kDa
Beobachtetes Molekulargewicht 48 kDa
GenBank-ZugangsnummerBC011901
Gene symbol Cytokeratin 17
Gene ID (NCBI) 3872
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS with 0.02% sodium azide and 50% glycerol
LagerungsbedingungenBei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Keratins are a large family of proteins that form the intermediate filaments that make up the cytoskeleton. Type I keratins are a group of acidic intermediate filament proteins and type II keratins are the basic or neutral counterparts. Keratin 17 is encoded by the KRT17 gene and is a type I cytokeratin found in nail beds, hair follicles, sebaceous glands, and epidermal appendages.

 What is the molecular weight of cytokeratin 17?

The molecular weight of cytokeratin 17 is approximately 49 kDa.

 What is the function of cytokeratin 17?

Cytokeratin 17 plays a role in the formation and maintenance of epidermal appendages, especially in determining the shape and orientation of hair. It is required for the maintenance of the anagen (growth) state of hair follicles by modulating the function of TNF-alpha for hair cycling and is also involved in tissue repair (PMID: 16702408).

 What is the cellular localization of cytokeratin 17?

Cytokeratin 17 expression is located in the cytoplasm.

 What is the tissue specificity of cytokeratin 17?

Cytokeratin 17 expression is found in the outer root sheath and medulla regions of the hair follicle, particularly in the eyebrow, beard, nail bed epithelium, basal cells of the oral epithelium, and sweat and mammary glands (PMID: 2451629). Expression can also be found in epithelial layers of the prostate and urinary bladder and cambial cells of the sebaceous gland at the protein level.

 What is the role of cytokeratin 17 in disease?

Mutations in the KRT17 gene are a cause of Jackson-Lawler type pachyonychia congenita type 2 (PC2); an autosomal dominant ectodermal dysplasia characterized by hypertrophic nail dystrophy (PMID: 7539673). Defects in KRT17 also lead to steatocystoma multiplex (SM) (PMID: 9767294). Cytokeratin 17 acts as an autoantigen in the immunopathogenesis of psoriasis (PMID: 23722817).


Protokolle

PRODUKTSPEZIFISCHE PROTOKOLLE
WB protocol for Cytokeratin 17 antibody 18502-1-APProtokoll herunterladen
IHC protocol for Cytokeratin 17 antibody 18502-1-APProtokoll herunterladenl
IF protocol for Cytokeratin 17 antibody 18502-1-APProtokoll herunterladen
IP protocol for Cytokeratin 17 antibody 18502-1-APProtokoll herunterladen
FC protocol for Cytokeratin 17 antibody 18502-1-APDownload protocol
STANDARD-PROTOKOLLE
Klicken Sie hier, um unsere Standardprotokolle anzuzeigen

Publikationen

SpeciesApplicationTitle
goatIF

J Anim Sci Biotechnol

Establishment of goat mammary organoid cultures modeling the mammary gland development and lactation

Authors - Lei Jia
human,mouseWB,IHC,IF,ELISA

J Endocr Soc

KRT17 From Keratinocytes With High Glucose Stimulation Inhibit Dermal Fibroblasts Migration Through Integrin α11

Authors - Peng Zhou
humanWB,IHC

Research (Wash D C)

Aggregation-Induced Emission-Active Photosensitizer-Mediated Photodynamic Therapy for Anti-Psoriasis

Authors - Ping Zhu
humanIF

J Inflamm Res

CORM-3 Inhibits the Inflammatory Response of Human Periodontal Ligament Fibroblasts Stimulated by LPS and High Glucose

Authors - Haoyang Tian

Rezensionen

The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.


FH

Karlheinz (Verified Customer) (08-24-2025)

pAB material was preliminary tested on a Test line for a preliminary LFA for K17 recognition, by a manual dot with a 1 uL pipette on a nitrocellulose membrane. Despite its low concentration, pAB 0.35 mg/mL (instead of the usual 1 mg/mL), it captured MillePore Estaphore intense red PS microsphere conjugated to proprietary K17 mAB, proving it was compatible with the K17 recombinant protein, even if it had a His tag attached, and the proprietary K17 mAB.

  • Applications: Other
  • Primary Antibody Dilution: used undiluted
  • Cell Tissue Type: NA, K17 was spike in synthetic urine for preliminary LFA application compatibility testing
Cytokeratin 17 Antibody Other validation (used undiluted dilution) in NA, K17 was spike in synthetic urine for preliminary LFA application compatibility testing (Cat no:18502-1-AP)